Database : MEDLINE
Search on : mumps [Words]
References found : 12435 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 1244 go to page                         

  1 / 12435 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29506477
[Au] Autor:Giaquinto C; Gabutti G; Baldo V; Villa M; Tramontan L; Raccanello N; Russo F; Poma C; Scamarcia A; Cantarutti L; Lundin R; Perinetti E; Cornen X; Thomas S; Ballandras C; Souverain A; Hartwig S
[Ad] Address:Department of Women and Child Health, University of Padova, Padova, Italy.
[Ti] Title:Impact of a vaccination programme in children vaccinated with ProQuad, and ProQuad-specific effectiveness against varicella in the Veneto region of Italy.
[So] Source:BMC Infect Dis;18(1):103, 2018 Mar 05.
[Is] ISSN:1471-2334
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:BACKGROUND: Monovalent varicella vaccines have been available in the Veneto Region of Italy since 2004. In 2006, a single vaccine dose was added to the immunisation calendar for children aged 14 months. ProQuad®, a quadrivalent measles-mumps-rubella-varicella vaccine, was introduced in May 2007 and used, among other varicella vaccines, until October 2008. This study aimed to evaluate the effectiveness of a single dose of ProQuad, and the population impact of a vaccination program (VP) against varicella of any severity in children who received a first dose of ProQuad at 14 months of age in the Veneto Region, METHODS: All children born in 2006/2007, i.e., eligible for varicella vaccination after ProQuad was introduced, were retrospectively followed through individual-level data linkage between the Pedianet database (varicella cases) and the Regional Immunization Database (vaccination status). The direct effectiveness of ProQuad was estimated as the incidence rate of varicella in ProQuad-vaccinated children aged < 6 years compared to children with no varicella vaccination from the same birth cohort. The impact of the VP on varicella was measured by comparing children eligible for the VP to an unvaccinated historical cohort from 1997/1998. The vaccine impact measures were: total effect (the combined effect of ProQuad vaccination and being covered by the Veneto VP); indirect effect (the effect of the VP on unvaccinated individuals); and overall effect (the effect of the VP on varicella in the entire population of the Veneto Region, regardless of their vaccination status). RESULTS: The adjusted direct effectiveness of ProQuad was 94%. The vaccine impact measures total, indirect, and overall effect were 97%, 43%, and 90%, respectively. CONCLUSIONS: These are the first results on the effectiveness and impact of ProQuad against varicella; data confirmed its high effectiveness, based on immunological correlates for protection. Direct effectiveness is our only ProQuad-specific measure; all impact measures refer at least partially to the VP and should be interpreted in the context of high vaccine coverage and the use of various varicella vaccines in this region. The Veneto Region offered a unique opportunity for this study due to an individual data linkage between Pedianet and the Regional Immunization database.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180311
[Lr] Last revision date:180311
[St] Status:In-Data-Review
[do] DOI:10.1186/s12879-018-3017-9

  2 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29521536
[Au] Autor:Mann BW
[Ad] Address:a Department of Communication , University of Utah.
[Ti] Title:Autism Narratives in Media Coverage of the MMR Vaccine-Autism Controversy under a Crip Futurism Framework.
[So] Source:Health Commun;:1-7, 2018 Mar 09.
[Is] ISSN:1532-7027
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:While previous studies in health communication have examined online news media regarding autism, there is a lack of research that critically examines how such media representations may stigmatize autism and seeks to eliminate the condition, particularly in the context of the resurging measles, mumps, and rubella (MMR) vaccine-autism controversy. To address this gap in the literature, this study analyzes 153 articles that engage the MMR vaccine-autism controversy from the top 10 online news sources in the U.S. from September 2015 through July 2017. It draws from Kafer's (2013) work in Feminist, Crip, Queer, using a lens of crip futurism to interpret three major narrative themes: a death and survival narrative that purports autism as a worst-case scenario, a societal problem narrative, and a preventative narrative that seeks to eliminate the condition. These themes suggest that online news media narratives about autism surrounding the autism-MMR controversy play into stereotypes about autism, including stigmatization and prioritization of preventive behaviors and cures over supporting the lived experiences of autistic individuals. Continued research on the impact of online media portrayals of autism specifically, and disability in health contexts generally, is called for.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:Publisher
[do] DOI:10.1080/10410236.2018.1449071

  3 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29458556
[Au] Autor:Abdel-Moneim AS; Soliman MS; Kamel MM; El-Kholy AA
[Ad] Address:1​Microbiology Department, College of Medicine, Taif University, Al-Taif 21944, Saudi Arabia.
[Ti] Title:Sequence analysis of the G gene of hRSVA ON1 genotype from Egyptian children with acute respiratory tract infections.
[So] Source:J Med Microbiol;67(3):387-391, 2018 Mar.
[Is] ISSN:1473-5644
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Human respiratory syncytial virus causes severe lower respiratory tract infection in neonates and children. Genotype ON1, with duplication of 72-nt in the G gene, was first detected in Canada and then recorded in other countries. In the current study, we describe the first detection of the ON1 genotype among children in Egypt in 2014/2015. Sequence analysis of the full-attachment G gene revealed that the majority of the strains examined were related to the ON1 genotype and only one sample related to N1 genotype. The Egyptian ON1 strains showed unique non-silent mutations in addition to variable mutations near the antigenic sites in comparison to the original ON1 ancestor strain. Continuous surveillance of hRSV regionally and globally is needed to understand the evolutionary mechanisms and strategies adopted by hRSV and their inducers for better adaption to the host.
[Mh] MeSH terms primary: Respiratory Syncytial Virus Infections/virology
Respiratory Syncytial Virus, Human/genetics
Respiratory Tract Infections/virology
Viral Fusion Proteins/genetics
[Mh] MeSH terms secundary: Canada/epidemiology
Child, Preschool
Egypt/epidemiology
Evolution, Molecular
Female
Genotype
Humans
Infant
Male
Mutation
Nasopharynx/virology
Phylogeny
Respiratory Syncytial Virus Infections/epidemiology
Respiratory Syncytial Virus, Human/isolation & purification
Respiratory Tract Infections/epidemiology
Sequence Alignment
Sequence Analysis, DNA
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (G glycoprotein, Respiratory syncytial virus); 0 (Viral Fusion Proteins)
[Em] Entry month:1803
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:180221
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000699

  4 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28465097
[Au] Autor:Cohet C; Rosillon D; Willame C; Haguinet F; Marenne MN; Fontaine S; Buyse H; Bauchau V; Baril L
[Ad] Address:GSK Vaccines, Wavre, Belgium. Electronic address: catherine.x.cohet@gsk.com.
[Ti] Title:Challenges in conducting post-authorisation safety studies (PASS): A vaccine manufacturer's view.
[So] Source:Vaccine;35(23):3041-3049, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Post-authorisation safety studies (PASS) of vaccines assess or quantify the risk of adverse events following immunisation that were not identified or could not be estimated pre-licensure. The aim of this perspective paper is to describe the authors' experience in the design and conduct of twelve PASS that contributed to the evaluation of the benefit-risk of vaccines in real-world settings. We describe challenges and learnings from selected PASS of rotavirus, malaria, influenza, human papillomavirus and measles-mumps-rubella-varicella vaccines that assessed or identified potential or theoretical risks, which may lead to changes to risk management plans and/or to label updates. Study settings include the use of large healthcare databases and de novo data collection. PASS methodology is influenced by the background incidence of the outcome of interest, vaccine uptake, availability and quality of data sources, identification of the at-risk population and of suitable comparators, availability of validated case definitions, and the frequent need for case ascertainment in large databases. Challenges include the requirement for valid exposure and outcome data, identification of, and access to, adequate data sources, and mitigating limitations including bias and confounding. Assessing feasibility is becoming a key step to confirm that study objectives can be met in a timely manner. PASS provide critical information for regulators, public health agencies, vaccine manufacturers and ultimately, individuals. Collaborative approaches and synergistic efforts between vaccine manufacturers and key stakeholders, such as regulatory and public health agencies, are needed to facilitate access to data, and to drive optimal study design and implementation, with the aim of generating robust evidence.
[Mh] MeSH terms primary: Adverse Drug Reaction Reporting Systems
Drug Industry/legislation & jurisprudence
Technology, Pharmaceutical/legislation & jurisprudence
Vaccines/adverse effects
[Mh] MeSH terms secundary: Chickenpox Vaccine/adverse effects
Humans
Influenza Vaccines/adverse effects
Malaria Vaccines/adverse effects
Measles-Mumps-Rubella Vaccine/adverse effects
Papillomavirus Vaccines/adverse effects
Risk Assessment
Rotavirus Vaccines/adverse effects
Technology, Pharmaceutical/methods
Technology, Pharmaceutical/organization & administration
Vaccination
Vaccines/administration & dosage
Vaccines, Attenuated
Vaccines, Combined/adverse effects
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Chickenpox Vaccine); 0 (Influenza Vaccines); 0 (Malaria Vaccines); 0 (Measles-Mumps-Rubella Vaccine); 0 (Papillomavirus Vaccines); 0 (Rotavirus Vaccines); 0 (Vaccines); 0 (Vaccines, Attenuated); 0 (Vaccines, Combined); 0 (measles, mumps, rubella, varicella vaccine)
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170504
[St] Status:MEDLINE

  5 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28461066
[Au] Autor:Gilbert NL; Rotondo J; Shapiro J; Sherrard L; Fraser WD; Ward BJ
[Ad] Address:Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, Canada; École de santé publique de l'Université de Montréal, Montreal, Canada. Electronic address: nicolas.gilbert@phac-aspc.gc.ca.
[Ti] Title:Seroprevalence of rubella antibodies and determinants of susceptibility to rubella in a cohort of pregnant women in Canada, 2008-2011.
[So] Source:Vaccine;35(23):3050-3055, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:Long term control of rubella and congenital rubella syndrome relies on high population-level immunity against rubella, particularly among women of childbearing age. In Canada, all pregnant women should be screened so that susceptible new mothers can be offered vaccination for rubella before discharge. This study was undertaken to estimate rubella susceptibility in a cohort of pregnant women in Canada and to identify associated socio-economic and demographic factors. Biobanked plasma samples were obtained from the Maternal-Infant Research on Environmental Chemicals (MIREC) study, in which pregnant women were recruited between 2008 and 2011. Socio-demographic characteristics and obstetric histories were collected. Second trimester plasma samples (n=1,752) were tested for rubella-specific IgG using an in-house enzyme-linked immunosorbent assay. The percentage of women with IgG titers <5IU/mL, 5-10IU/mL, and ≥10IU/mL were 2.3%, 10.1%, and 87.6%, respectively. Rates of seronegativity, defined as <5IU/mL, were 3.1% in women who had no previous live birth and 1.6% in women who had given birth previously. Among the latter group, seronegativity was higher in women with high school education or less (adjusted OR (aOR) 5.93, 95% CI 2.08-16.96) or with a college or trade school diploma (aOR 3.82, 95% CI 1.45-10.12), compared to university graduates, and those born outside Canada (aOR 2.60, 95% CI 1.07-6.31). In conclusion, a large majority of pregnant women were found to be immune to rubella. Further research is needed to understand inequalities in vaccine uptake or access, and more effort is needed to promote catch-up measles-mumps-rubella vaccination among socioeconomically disadvantaged and immigrant women of childbearing age.
[Mh] MeSH terms primary: Antibodies, Viral/blood
Disease Susceptibility
Pregnancy Complications, Infectious/immunology
Rubella/epidemiology
Rubella/immunology
[Mh] MeSH terms secundary: Adolescent
Adult
Canada/epidemiology
Cohort Studies
Educational Status
Enzyme-Linked Immunosorbent Assay
Female
Humans
Immunoglobulin G/blood
Middle Aged
Pregnancy
Pregnancy Complications, Infectious/prevention & control
Pregnancy Complications, Infectious/virology
Rubella/virology
Rubella Syndrome, Congenital/prevention & control
Seroepidemiologic Studies
Vaccination
Young Adult
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Antibodies, Viral); 0 (Immunoglobulin G); 0 (rubella antibodies)
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170503
[St] Status:MEDLINE

  6 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28457672
[Au] Autor:Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
[Ad] Address:Instituto Nacional de Salud Pública, Mexico. Electronic address: jdiaz@insp.mx.
[Ti] Title:Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
[So] Source:Vaccine;35(23):3116-3122, 2017 05 25.
[Is] ISSN:1873-2518
[Cp] Country of publication:Netherlands
[La] Language:eng
[Ab] Abstract:IMPORTANCE: In a previous study on booster vaccination, we reported that two aerosolized MMR vaccines were as safe and immunogenic as injectable vaccines containing the same antigens. We now present results of antibody persistence one year after immunization. OBJECTIVE: To assess the antibody persistence for measles, mumps, and rubella one year following booster immunization. METHODS: We performed clinical and serological follow-up of participants in a previous study of Mexican children aged 6-7years, in which participants were randomized to four groups receiving, by aerosolized or by injection, the MMR SII vaccine (Serum Institute of India), or the MMR II (Merck Sharp & Dhome). We evaluated the antibody persistence by PRN test for measles and by ELISA for rubella and mumps. The occurrence of clinical events was evaluated via periodic visits of a nurse team to children's schools and homes. RESULTS: Of the 260 initial participants, 241 completed one-year follow-up. There were only statistically significant differences in baseline seropositivity for mumps. One year after immunization, seropositivity in all groups was 100% for measles and rubella. The seropositivity rank for mumps was from 90.3% for the injected vaccine MMR II to 96.6% for vaccine MMR SII applied by aerosol; these differences were not statistically significant. With exception of the aerosolized vaccine MMR SII for the geometric mean titer (GMT) for measles, all study groups presented declination of GMT for the three viruses. The difference between the aerosolized vaccines MMR SII and MMR RII was statistically significant for mumps antibodies. Only mild clinical events were identified. CONCLUSION: Under conditions of no endemic transmission for measles and rubella, and of low circulation of mumps virus, school-aged children remained seropositive to the three viruses one year following booster immunization. The study was registered under CMN 2010-005 number at COFEPRIS (National Regulatory Authority).
[Mh] MeSH terms primary: Antibodies, Viral/blood
Immunization, Secondary/methods
Measles virus/immunology
Measles-Mumps-Rubella Vaccine/immunology
Mumps virus/immunology
[Mh] MeSH terms secundary: Aerosols
Child
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Humans
Immunization, Secondary/adverse effects
India/epidemiology
Injections
Male
Measles/epidemiology
Measles/immunology
Measles/prevention & control
Measles-Mumps-Rubella Vaccine/administration & dosage
Measles-Mumps-Rubella Vaccine/adverse effects
Mumps/epidemiology
Mumps/immunology
Mumps/prevention & control
Rubella/epidemiology
Rubella/immunology
Rubella/prevention & control
Rubella virus/immunology
Seroepidemiologic Studies
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Name of substance:0 (Aerosols); 0 (Antibodies, Viral); 0 (Measles-Mumps-Rubella Vaccine); 0 (rubella antibodies)
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170502
[St] Status:MEDLINE

  7 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29394383
[Au] Autor:Huber F; Ehrensperger B; Hatz C; Chappuis F; Bühler S; Eperon G
[Ad] Address:Epidemiology, Biostatistics and Prevention Institute, Department of Public Health, Division of Infectious Diseases/Travel Clinic, University of Zurich, Hirschengraben 84, 8001 Zurich, Switzerland.
[Ti] Title:Safety of live vaccines on immunosuppressive or immunomodulatory therapy-a retrospective study in three Swiss Travel Clinics.
[So] Source:J Travel Med;25(1), 2018 Jan 01.
[Is] ISSN:1708-8305
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:Background: Patients increasingly benefit from immunosuppressive/immunomodulatory medications for a range of conditions allowing them a lifestyle similar to healthy individuals, including travel. However, the administration of live vaccines to immunodeficient patients bears the risk of replication of the attenuated vaccine microorganism. Therefore, live vaccines are generally contraindicated on immunosuppression. Data on live vaccinations on immunosuppressive/immunomodulatory medication are scarce. We identified all travellers seeking pre-travel advice in three Swiss travel clinics with a live vaccine during immunosuppressive/immunomodulatory therapy to ascertain experienced side effects. A retrospective and multi-centre study design was chosen to increase the sample size. Methods: This study was conducted in the travel clinics of the University of Zurich; the Swiss TPH, Basel; and Geneva University Hospitals. Travellers on immunosuppressive/immunomodulatory therapy who received live vaccines [yellow fever vaccination (YFV), measles/mumps/rubella (MMR), varicella and/ or oral typhoid vaccination (OTV)] between 2008 and 2015 were identified and interviewed. A total of 60 age- and sex-matched controls (matched to Basel/Zurich travel clinics travellers) were included. Results: Overall, 197 patients were identified. And 116 patients (59%) and 60 controls were interviewed. YFV was administered 92 times, MMR 21 times, varicella 4 times and OTV 6 times to patients on immunosuppressive/immunomodulatory therapy. Most common medications were corticosteroids (n = 45), mesalazine (n = 28) and methotrexate (n = 19). Live vaccines were also administered on biological treatment, e.g. TNF-alpha inhibitors (n = 8). Systemic reactions were observed in 12.2% of the immunosuppressed vs 13.3% of controls; local reactions in 7.8% of the immunosuppressed vs 11.7% of controls. In controls, all reactions were mild/moderate. In the immunosuppressed, 2/21 severe reactions occurred: severe local pain on interferon-beta and severe muscle/joint pain on sulfasalazine. Conclusion: Safety of live vaccines given to immunosuppressed patients cannot be concluded. However, it is re-assuring that in the examined patient groups no serious side effects or infections by the attenuated vaccine strain occurred.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1802
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:In-Data-Review
[do] DOI:10.1093/jtm/tax082

  8 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29363797
[Au] Autor:Vaidya SR; Hamde VS; Kumbhar NS; Walimbe AM
[Ad] Address:Indian Council of Medical Research-National Institute of Virology, 20-A Dr. Ambedkar Road, Pune 411001, India.
[Ti] Title:Utility of neutralization test for laboratory diagnosis of suspected mumps.
[So] Source:Microbiol Immunol;, 2018 Jan 24.
[Is] ISSN:1348-0421
[Cp] Country of publication:Australia
[La] Language:eng
[Ab] Abstract:Mumps is an infectious disease caused by mumps virus (MuV), which belongs to the family Paramyxoviridae and genus Rubulavirus. Typical symptoms of mumps include fever and swelling of the parotid glands; however, mumps can be asymptomatic. Mumps is diagnosed by molecular and serological methods (i.e., PCR and Enzyme Immunoassay [EIA]); however, both methods have pros and cons. This study was performed to compare the diagnostic utility of a focus reduction neutralization test (FRNT) to that of MuV-specific commercial IgM and IgG antibody EIA in patients suspected of having mumps. One hundred-eighty six samples collected during mumps outbreak in 2012-16 were studied. Samples (n = 80) were tested by all the three serological assays and showed 70.4%, 83% and 92.5% positivity by IgM EIA, IgG and FRNT, respectively. In all, 58.8% samples (n = 47) tested positive in all three assays. Concordance between mumps RT-PCR and IgM EIA was highest during the first 2-5 days and decreased with increasing time post-onset. Mumps FRNT results agreed with those of RT-PCR/IgM EIA from the second week onwards, whereas the results of mumps IgG EIA agreed with those of RT-PCR/IgM EIA from post-onset days 3-10. These findings suggest the utility of a FRNT for laboratory diagnosis of mumps in countries whose populations are not immunized against this infection.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1801
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[St] Status:Publisher
[do] DOI:10.1111/1348-0421.12576

  9 / 12435 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29512485
[Au] Autor:Saito N; Takamura N; Retuerma GP; Frayco CH; Solano PS; Ubas CD; Lintag AV; Ribo MR; Solante RM; Dimapilis AQ; Telan EO; Go WS; Suzuki M; Ariyoshi K; Parry CM
[Ad] Address:School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan.
[Ti] Title:Frequent Community Use of Antibiotics among a Low-Economic Status Population in Manila, the Philippines: A Prospective Assessment Using a Urine Antibiotic Bioassay.
[So] Source:Am J Trop Med Hyg;, 2018 Mar 05.
[Is] ISSN:1476-1645
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The widespread unregulated use of antibiotics without medical consultation contributes to the burden of antibiotic resistance in Southeast Asian countries. This study investigated antibiotic use before hospital consultation. In a prospective observational study from February 2, 2015, to July 2, 2015, we enrolled febrile patients attending the emergency room in San Lazaro Hospital, Manila, the Philippines. A urine sample was collected and a bioassay was used to detect antibiotic activity in urine using (ATCC7953), (ATCC25922), and (ATCC19615). Patients or caregivers reported their medication history, clinical information, and socioeconomic status. During the study period, 410 patients were enrolled. The median (interquartile range) age was 14 (7-23) years and 158 (39%) reported prior antibiotic use, predominantly a beta-lactam antibiotic. A total of 164 (40%, 95% confidence interval [CI]: 35-45) patients were urine bioassay positive with any of three organisms. The assay was the most sensitive, detecting 162 (99%, 95% CI: 96-100) cases. Among bioassay positive patients, dengue ( = 91, 55%, 95% CI: 48-63) was the most frequent diagnosis, followed by other viral infections, including measles, rubella, and mumps ( = 17, 10%, 95% CI: 6-16). Patients with a positive bioassay were significantly more likely to be from the lowest-income group (adjusted odds ratio [AOR]: 1.7; 95% CI: 1.1-2.6) and required hospital admission (AOR: 2.1; 95% CI: 1.3-3.5). Unnecessary antibiotic use for febrile illnesses before hospital consultation is common in a low-income, highly populated urban community in Manila. Education targeting this group should be implemented to reduce unnecessary antibiotic use.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[St] Status:Publisher
[do] DOI:10.4269/ajtmh.17-0564

  10 / 12435 MEDLINE  
              first record previous record
select
to print
Photocopy

[PMID]: 29509821
[Au] Autor:Campos-Outcalt D
[Ad] Address:University of Arizona, Phoenix, AZ, USA. E-mail: dougco@email.arizona.edu.
[Ti] Title:Practice Alert: ACIP vaccine update.
[So] Source:J Fam Pract;67(3):155-158, 2018 Mar.
[Is] ISSN:1533-7294
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:The Advisory Committee on Immunization Practices made relatively few new vaccine recommendations in 2017. One pertained to prevention of hepatitis B virus infection in infants born to HBV-infected mothers. Another recommended a new vaccine to prevent shingles. A third advised considering an additional dose of mumps vaccine during an outbreak.
[Pt] Publication type:PRACTICE GUIDELINE
[Em] Entry month:1803
[Cu] Class update date: 180306
[Lr] Last revision date:180306
[St] Status:In-Data-Review


page 1 of 1244 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information